GlassScriptPhysician profile
Young J Cho
NPI 1205858925
$4,796.17
in general payments reported to CMS, 2019-2025
35 companies · $561 in 2025
The $561 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,951 · 2020: $551 · 2021: $258 · 2022: $661 · 2023: $594 · 2024: $220 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,250.22 |
| Education | $124.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $519.80 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $480.37 | 2019-2025 | Austedo Xr, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $448.58 | 2019-2023 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $435.77 | 2019-2025 | |
| Lilly USA, LLC | $374.00 | 2019-2024 | Emgality |
| Biogen, INC. | $330.51 | 2019-2025 | Vumerity |
| Sk Life Science, INC. | $305.95 | 2022-2025 | Xcopri |
| Argenx US, INC. | $290.52 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Genzyme Corporation | $249.56 | 2019 | |
| Amgen INC. | $140.40 | 2019-2020 | |
| Daiichi Sankyo INC. | $134.97 | 2022 | |
| Vanda Pharmaceuticals INC. | $125.00 | 2025 | Ponvory |
| Emd Serono, INC. | $121.84 | 2023 | Mavenclad |
| Eisai INC. | $110.00 | 2024 | |
| Supernus Pharmaceuticals, INC. | $86.24 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $68.46 | 2019-2023 | |
| Acorda Therapeutics, INC | $58.69 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $49.82 | 2021 | |
| Abbvie INC. | $48.07 | 2023-2024 | Qulipta, Ubrelvy |
| Neurelis, INC. | $44.09 | 2023-2024 | Valtoco |
| Tersera Therapeutics LLC | $40.06 | 2019 | |
| Neurocrine Biosciences, INC. | $36.30 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $34.46 | 2019-2025 | Nuplazid |
| Adamas Pharmaceuticals, INC. | $27.94 | 2019 | |
| Allergan, INC. | $26.51 | 2020 | |
| Grifols USA, LLC | $23.43 | 2023 | Gamunex-C |
| Mallinckrodt Hospital Products INC. | $23.21 | 2020 | |
| Mallinckrodt Enterprises LLC | $22.03 | 2019 | |
| Harmony Biosciences LLC | $20.54 | 2023 | Wakix |
| Genentech USA, INC. | $15.71 | 2019 | |
| Tanabe Pharma America, INC. | $15.36 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.11 | 2019 | |
| Portola Pharmaceuticals, LLC | $12.06 | 2019 | |
| Horizon Therapeutics Plc | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.